Assessing the quality and value of metabolic chart data for capturing core outcomes for pediatric medium-chain acyl-CoA dehydrogenase (MCAD) deficiency.
Core outcome set
Data quality
MCAD deficiency
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
13 Jan 2024
13 Jan 2024
Historique:
received:
19
05
2023
accepted:
27
10
2023
medline:
13
1
2024
pubmed:
13
1
2024
entrez:
12
1
2024
Statut:
epublish
Résumé
Generating rigorous evidence to inform care for rare diseases requires reliable, sustainable, and longitudinal measurement of priority outcomes. Having developed a core outcome set for pediatric medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, we aimed to assess the feasibility of prospective measurement of these core outcomes during routine metabolic clinic visits. We used existing cohort data abstracted from charts of 124 children diagnosed with MCAD deficiency who participated in a Canadian study which collected data from birth to a maximum of 11 years of age to investigate the frequency of clinic visits and quality of metabolic chart data for selected outcomes. We recorded all opportunities to collect outcomes from the medical chart as a function of visit rate to the metabolic clinic, by treatment centre and by child age. We applied a data quality framework to evaluate data based on completeness, conformance, and plausibility for four core MCAD outcomes: emergency department use, fasting time, metabolic decompensation, and death. The frequency of metabolic clinic visits decreased with increasing age, from a rate of 2.8 visits per child per year (95% confidence interval, 2.3-3.3) among infants 2 to 6 months, to 1.0 visit per child per year (95% confidence interval, 0.9-1.2) among those ≥ 5 years of age. Rates of emergency department visits followed anticipated trends by child age. Supplemental findings suggested that some emergency visits occur outside of the metabolic care treatment centre but are not captured. Recommended fasting times were updated relatively infrequently in patients' metabolic charts. Episodes of metabolic decompensation were identifiable but required an operational definition based on acute manifestations most commonly recorded in the metabolic chart. Deaths occurred rarely in these patients and quality of mortality data was not evaluated. Opportunities to record core outcomes at the metabolic clinic occur at least annually for children with MCAD deficiency. Methods to comprehensively capture emergency care received at outside institutions are needed. To reduce substantial heterogeneous recording of core outcome across treatment centres, improved documentation standards are required for recording of recommended fasting times and a consensus definition for metabolic decompensations needs to be developed and implemented.
Sections du résumé
BACKGROUND
BACKGROUND
Generating rigorous evidence to inform care for rare diseases requires reliable, sustainable, and longitudinal measurement of priority outcomes. Having developed a core outcome set for pediatric medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, we aimed to assess the feasibility of prospective measurement of these core outcomes during routine metabolic clinic visits.
METHODS
METHODS
We used existing cohort data abstracted from charts of 124 children diagnosed with MCAD deficiency who participated in a Canadian study which collected data from birth to a maximum of 11 years of age to investigate the frequency of clinic visits and quality of metabolic chart data for selected outcomes. We recorded all opportunities to collect outcomes from the medical chart as a function of visit rate to the metabolic clinic, by treatment centre and by child age. We applied a data quality framework to evaluate data based on completeness, conformance, and plausibility for four core MCAD outcomes: emergency department use, fasting time, metabolic decompensation, and death.
RESULTS
RESULTS
The frequency of metabolic clinic visits decreased with increasing age, from a rate of 2.8 visits per child per year (95% confidence interval, 2.3-3.3) among infants 2 to 6 months, to 1.0 visit per child per year (95% confidence interval, 0.9-1.2) among those ≥ 5 years of age. Rates of emergency department visits followed anticipated trends by child age. Supplemental findings suggested that some emergency visits occur outside of the metabolic care treatment centre but are not captured. Recommended fasting times were updated relatively infrequently in patients' metabolic charts. Episodes of metabolic decompensation were identifiable but required an operational definition based on acute manifestations most commonly recorded in the metabolic chart. Deaths occurred rarely in these patients and quality of mortality data was not evaluated.
CONCLUSIONS
CONCLUSIONS
Opportunities to record core outcomes at the metabolic clinic occur at least annually for children with MCAD deficiency. Methods to comprehensively capture emergency care received at outside institutions are needed. To reduce substantial heterogeneous recording of core outcome across treatment centres, improved documentation standards are required for recording of recommended fasting times and a consensus definition for metabolic decompensations needs to be developed and implemented.
Identifiants
pubmed: 38216926
doi: 10.1186/s12887-023-04393-4
pii: 10.1186/s12887-023-04393-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
37Subventions
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Informations de copyright
© 2024. The Author(s).
Références
Horvath GA, Davidson AGF, Stockler-Ipsiroglu SG, Lillquist YP, Waters PJ, Olpin S, et al. Newborn screening for MCAD deficiency: Experience of the first three years in British Columbia, Canada. Can J Public Heal. 2008;99(4):276–80.
doi: 10.1007/BF03403754
Kennedy S, Potter BK, Wilson K, Fisher L, Geraghty M, Milburn J, et al. The first three years of screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) by newborn screening ontario. BMC Pediatr. 2010;10:82.
doi: 10.1186/1471-2431-10-82
pubmed: 21083904
pmcid: 2996355
Zschocke J, Schulze A, Lindner M, Fiesel S, Olgemöller K, Hoffman GF, et al. Molecular and functional characterisation of mild MCAD deficiency. Hum Genet. 2001;108(5):404–8.
doi: 10.1007/s004390100501
pubmed: 11409868
Merritt JL 2nd, Chang IJ. Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1424/ . Updated 2019 Jun 27.
Piercy H, Machaczek K, Ali P, Yap S. Parental experiences of raising a child with medium chain Acyl-CoA dehydrogenase deficiency. Glob Qual Nurs Res. 2017;4:2333393617707080.
pubmed: 28516128
pmcid: 5419063
Schatz UA, Ensenauer R. The clinical manifestation of MCAD deficiency: Challenges towards adulthood in the screened population. J Inherit Metab Dis. 2010;33(5):513–20.
doi: 10.1007/s10545-010-9115-5
pubmed: 20532824
Iafolla AK, Thompson RJ, Roe CR. Medium-chain acyl-coenzyme A dehydrogenase deficiency: Clinical course in 120 affected children. J Pediatr. 1994;124(3):409–15.
doi: 10.1016/S0022-3476(94)70363-9
pubmed: 8120710
McGregor TL, Berry SA, Dipple KM, Hamid R. Management principles for acute illness in patients with medium-chain acyl-coenzyme a dehydrogenase deficiency. Pediatrics. 2021;147(1): e2020040303.
doi: 10.1542/peds.2020-040303
pubmed: 33372121
Batten W, Chronopoulou E, Pierre G. P37 A single paediatric centre experience of l-carnitine supplementation in medium-chain acyl-coa dehydrogenase deficiency (mcadd). Arch Dis Child. 2018;103: e2.
doi: 10.1136/archdischild-2017-314585.46
Lee PJ, Harrison EL, Jones MG, Jones S, Leonard JV, Chalmers RA. L-Carnitine and exercise tolerance in medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency: A pilot study. J Inherit Metab Dis. 2005;28(2):141–52.
doi: 10.1007/s10545-005-5262-5
pubmed: 15877203
Madsen KL, Preisler N, Orngreen MC, Andersen SP, Olesen JH, Lund AM, et al. Patients with medium-chain acyl-coenzyme a dehydrogenase deficiency have impaired oxidation of fat during exercise but no effect of L-Carnitine supplementation. J Clin Endocrinol Metab. 2013;98(4):1667–75.
doi: 10.1210/jc.2012-3791
pubmed: 23426616
Potter BK, Little J, Chakraborty P, Kronick JB, Evans J, Frei J, et al. Variability in the clinical management of fatty acid oxidation disorders: Results of a survey of Canadian metabolic physicians. J Inherit Metab Dis. 2012;35(1):115–23.
doi: 10.1007/s10545-011-9352-2
pubmed: 21630065
Potter BK, Khangura SD, Tingley K, Chakraborty P, Little J. Translating rare-disease therapies into improved care for patients and families: What are the right outcomes, designs, and engagement approaches in health-systems research? Genet Med. 2016;18(2):117–23.
doi: 10.1038/gim.2015.42
pubmed: 25856667
Clarke M, Williamson PR. Core outcome sets and systematic reviews. Syst Rev. 2016;5:11.
doi: 10.1186/s13643-016-0188-6
pubmed: 26792080
pmcid: 4719739
Prinsen CAC, Vohra S, Rose MR, King-Jones S, Ishaque S, Bhaloo Z, et al. Core Outcome Measures in Effectiveness Trials (COMET) initiative: Protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a “core outcome set.” Trials. 2014;15:247.
doi: 10.1186/1745-6215-15-247
pubmed: 24962012
pmcid: 4082295
Kodra Y, Weinbach J, Posada-De-La-Paz M, Coi A, Lemonnier SL, van Enckevort D, et al. Recommendations for improving the quality of rare disease registries. Int J Environ Res Public Health. 2018;15(8):1644.
doi: 10.3390/ijerph15081644
pubmed: 30081484
pmcid: 6121483
Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al. The COMET Handbook: Version 1.0. Trials. 2017;18(Suppl 3):280.
doi: 10.1186/s13063-017-1978-4
pubmed: 28681707
pmcid: 5499094
Pugliese M, Tingley K, Chow A, Pallone N, Smith M, Rahman A, et al. Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review. Orphanet J Rare Dis. 2020;15(1):12.
doi: 10.1186/s13023-019-1276-1
pubmed: 31937333
pmcid: 6961328
Pugliese M, Tingley K, Chow A, Pallone N, Smith M, Chakraborty P, et al. Core Outcome Sets for Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Phenylketonuria. Pediatrics. 2021;148(2): e2020037747.
doi: 10.1542/peds.2020-037747
pubmed: 34266901
Karaceper MD, Khangura SD, Wilson K, Coyle D, Brownell M, Davies C, et al. Health services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: A cohort study in Ontario, Canada. Orphanet J Rare Dis. 2019;14(1):70.
doi: 10.1186/s13023-019-1001-0
pubmed: 30902101
pmcid: 6431026
Prinsen CAC, Vohra S, Rose MR, Boers M, Tugwell P, Clarke M, et al. How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” - a practical guideline. Trials. 2016;17(1):449.
doi: 10.1186/s13063-016-1555-2
pubmed: 27618914
pmcid: 5020549
Tingley K, Lamoureux M, Pugliese M, Geraghty M, Kronick J, Potter B, et al. Evaluation of the quality of clinical data collection for a pan-Canadian cohort of children affected by inherited metabolic diseases: Lessons learned from the Canadian Inherited Metabolic Diseases Research Network. Orphanet J Rare Dis. 2020;15(1):89.
doi: 10.1186/s13023-020-01358-z
pubmed: 32276663
pmcid: 7149838
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377–81.
doi: 10.1016/j.jbi.2008.08.010
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.
doi: 10.1016/j.jbi.2019.103208
pubmed: 31078660
pmcid: 7254481
Kahn MG, Callahan TJ, Barnard J, Bauck AE, Brown J, Davidson BN, et al. A Harmonized Data Quality Assessment Terminology and Framework for the Secondary Use of Electronic Health Record Data. eGEMs. 2016;4(1):1244.
doi: 10.13063/2327-9214.1244
pubmed: 27713905
pmcid: 5051581
Derks TGJ, Van Spronsen FJ, Rake JP, Van Der Hilst CS, Span MM, Smit GPA. Safe and unsafe duration of fasting for children with MCAD deficiency. Eur J Pediatr. 2007;166(1):5–11.
doi: 10.1007/s00431-006-0186-0
pubmed: 16788829
McHugh ML. Interrater reliability: The kappa statistic. Biochem Medica. 2012;22(3):276–82.
doi: 10.11613/BM.2012.031
Wang SS. Medium chain acyl-CoA dehydrogenase deficiency: Human genome epidemiology review. Genet Med. 1999;1(7):332–9.
doi: 10.1097/00125817-199911000-00004
pubmed: 11263545
Klose DA, Kölker S, Heinrich B, Prietsch V, Mayatepek E, Von Kries R, et al. Incidence and short-term outcome of children with symptomatic presentation of organic acid and fatty acid oxidation disorders in Germany. Pediatrics. 2002;110(6):1204–11.
doi: 10.1542/peds.110.6.1204
pubmed: 12456920
Dyack S. Expanded newborn screening: Lessons learned from MCAD deficiency. Paediatr Child Health. 2004;9(4):241–3.
doi: 10.1093/pch/9.4.241
pubmed: 19655016
pmcid: 2720504
Derks TGJ, Reijngoud DJ, Waterham HR, Gerver WJM, van den Berg MP, Sauer PJJ, et al. The natural history of medium-chain acyl CoA dehydrogenase deficiency in the Netherlands: Clinical presentation and outcome. J Pediatr. 2006;148(5):665–70.
doi: 10.1016/j.jpeds.2005.12.028
pubmed: 16737882
Allori AC, Kelley T, Meara JG, Albert A, Bonanthaya K, Chapman K, et al. A standard set of outcome measures for the comprehensive appraisal of cleft care. Cleft Palate Craniofac J. 2017;54(5):540–54.
doi: 10.1597/15-292
pubmed: 27223626
Grosse SD, Khoury MJ, Greene CL, Crider KS, Pollitt RJ. The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: An update. Genet Med. 2006;8(4):205–12.
doi: 10.1097/01.gim.0000204472.25153.8d
pubmed: 16617240
Pan L, Fergusson D, Schweitzer I, Hebert PC. Ensuring high accuracy of data abstracted from patient charts: The use of a standardized medical record as a training tool. J Clin Epidemiol. 2005;58(9):918–23.
doi: 10.1016/j.jclinepi.2005.02.004
pubmed: 16085195